<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T12:05:22Z</responseDate>
  <request identifier="oai:figshare.com:article/33719065" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33719065</identifier>
        <datestamp>2026-09-14T05:40:37Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 1_Case Report: Neurosyphilis with a paraparetic Guillain-Barré-spectrum phenotype and CSF-detected anti-GT1a IgG: an infection-autoimmunity diagnostic challenge.docx</dc:title>
          <dc:creator>Xing Zhao (219333)</dc:creator>
          <dc:creator>Yizhi Zhang (172297)</dc:creator>
          <dc:creator>Wenjing Xie (1935859)</dc:creator>
          <dc:creator>Fei Yin (179978)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>anti-GT1a antibody</dc:subject>
          <dc:subject>blood-CSF barrier</dc:subject>
          <dc:subject>case report</dc:subject>
          <dc:subject>Guillain-Barré syndrome</dc:subject>
          <dc:subject>neurosyphilis</dc:subject>
          <dc:subject>polyradiculoneuropathy</dc:subject>
          <dc:description>Background&lt;p&gt;Active central nervous system (CNS) infection can resemble acute immune polyradiculoneuropathy, and the two processes may coexist. We describe a patient with neurosyphilis, rapidly progressive paraparetic weakness, and anti-GT1a IgG detected in cerebrospinal fluid (CSF) but not serum by a qualitative line immunoblot.&lt;/p&gt;Case presentation&lt;p&gt;A 41-year-old man developed rapidly progressive paraparesis, urinary retention, and left abducens palsy. On hospital day 2, CSF opening pressure was 260 mmH&lt;sub&gt;2&lt;/sub&gt;O, protein 1.56 g/L, white-cell count 272 × 10&lt;sup&gt;6&lt;/sup&gt;/L, CSF TPPA was reactive, and CSF RPR was 1:8. Penicillin and methylprednisolone were started after the first lumbar puncture. By day 8, CSF white-cell count and protein had fallen during overlapping antimicrobial and corticosteroid treatment, but opening pressure remained 260 mmH&lt;sub&gt;2&lt;/sub&gt;O and neurological deficits persisted. Paired serum-CSF testing showed marked blood-CSF barrier dysfunction (QAlb 17.4 × 10&lt;sup&gt;-3&lt;/sup&gt;), a type IV oligoclonal-band pattern, a Reiber-derived intrathecal IgM fraction of 35%, and anti-GT1a IgG detected in CSF but not serum. Day-11 electrodiagnostic testing showed reduced lower-limb motor amplitudes, preserved sensory responses, and absent F waves; a stable GBS electrophysiological subtype could not be assigned. Initial spinal MRI was normal; repeat lumbar MRI about 20 days later showed smooth enhancement along the ventral conus and cauda equina roots. IVIG was given on days 11-15; improvement was documented by day 30, and at 2 years the patient reported return to normal life and work.&lt;/p&gt;Conclusion&lt;p&gt;Neurosyphilis can present with a paraparetic GBS-spectrum phenotype, making it difficult to determine whether syphilitic meningoradiculitis alone explains the syndrome or whether a concurrent immune polyradiculoneuropathy is also present. In this setting, blood-CSF barrier dysfunction, CSF-detected anti-GT1a IgG, and improvement after IVIG should be viewed as hypothesis-generating observations rather than proof of antibody compartmentalization, dual pathology, or treatment causality. In similar cases, longitudinal clinical follow-up, electrophysiology, imaging, and quantitatively validated paired serum-CSF immune testing are needed to distinguish a single infectious process, a concurrent immune neuropathy, and a biologically linked infection-autoimmunity process.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-14T05:40:37Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1936622.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_1_Case_Report_Neurosyphilis_with_a_paraparetic_Guillain-Barr_-spectrum_phenotype_and_CSF-detected_anti-GT1a_IgG_an_infection-autoimmunity_diagnostic_challenge_docx/33719065</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
